ESC recently learned that proposed changes to the way drug prices are set in Canada (also know as Patented Medicines Regulations) may negatively impact Canadians living with atopic dermatitis (AD), commonly referred to as eczema.
In response, ESC has provided our input to the federal government on this important topic. We want them to know why changes to drug price regulations could harm Canadian eczema patients and their ability to access to new and innovative medicines.
As part of this effort, ESC recently sent a letter to the Patented Medicine Prices Review Board (PMPRB) that provides feedback on how these changes could mean significant consequences to patient care. ESC continues to advocate for better patient care and treatment options, and this includes improving access to new breakthrough medications.
